Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
09 Aug 2022, Darmstadt, Germany: Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a
full viral vector manufacturing offering including AAV, Lentiviral,
CDMO, CTO, and process development. This new platform enables
biopharmaceutical companies to increase the speed to clinical
manufacturing while reducing process development time and costs.
More info >> |